Abstract
Introduction
To compare the effect of bowel resection vs stripping on the clinical outcomes of patients with FIGO II–IV ovarian cancer.
Methods
We retrospectively analyzed patients with FIGO II–IV ovarian cancer who suffered from bowel involvement and underwent cytoreductive surgery between January 2014 and March 2022. Patients’ survival was compared by Kaplan–Meier survival analysis and Cox proportional hazards models.
Results
Four hundred and twelve patients were included. 48 patients underwent bowel resection (BR), and 364 patients underwent bowel tumor stripping (BTS). The BR group had longer operative duration, hospital stay, time to post-operative chemotherapy, and more intraoperative bleeding. The median PFS was 37 months (95% CI 12–62) in BTS compared to 25 months (95% CI 10–40) in BR among patients who achieved R0 resection (p = 0.590). Among those with R1 resection, the median PFS in BST was 23 months (95% CI 16–30) and that in BR was 15 months (95% CI 12–18, p = 0.136); moreover, a favorable median PFS was observed in BTS with residual bowel lesions (23 months, 95% CI 14–32), compared to BR (15 months, 95% CI 12–18, p = 0.144). Multivariate analysis indicated that FIGO stage, PCI, cytoreduction time and residual lesions were independent prognostic factors of PFS.
Conclusion
For patients with FIGO stage II–IV ovarian cancer with bowel implicated, bowel resection is necessary to achieve complete removal to improve the survival. If complete resection was judged unfeasible, cautious decision of bowel resection is required. Neoadjuvant chemotherapy might reduce the ratio of bowel resection for some with mesenteric involvement.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All data relevant to the study are included in the article or uploaded as supplementary information.
References
Aletti GD, Podratz KC, Jones MB, Cliby WA (2006) Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. J Am Coll Surg 203(4):521–526. https://doi.org/10.1016/j.jamcollsurg.2006.06.027
Aletti GD, Podratz KC, Moriarty JP, Cliby WA, Long KH (2009) Aggressive and complex surgery for advanced ovarian cancer: an economic analysis. Gynecol Oncol 112(1):16–21. https://doi.org/10.1016/j.ygyno.2008.10.008
Bacalbasa N, Balescu I, Dima S, Herlea V, David L, Brasoveanu V, Popescu I (2015a) Initial incomplete surgery modifies prognosis in advanced ovarian cancer regardless of subsequent management. Anticancer Res 35(4):2315–2320
Bacalbasa N, Dima S, Balescu I, David L, Brasoveanu V, Popescu I (2015b) Results of primary cytoreductive surgery in advanced-stage epithelial ovarian cancer: a single-center experience. Anticancer Res 35(7):4099–4104
Bacalbasa N, Balescu I, Dima S (2017) Rectosigmoidian involvement in advanced-stage ovarian cancer—intraoperative decisions. In Vivo 31(5):973–977. https://doi.org/10.21873/invivo.11156
Bacalbasa N, Balescu I, Diaconu C, Iliescu L, Filipescu A, Pop C, Dima S, Vilcu M, Brezean I (2020) Right upper abdominal resections in advanced stage ovarian cancer. In Vivo 34(3):1487–1492. https://doi.org/10.21873/invivo.11934
Bachmann R, Rothmund R, Kramer B, Brucker SY, Konigsrainer A, Konigsrainer I, Beckert S, Staebler A, NguyenHuu P, Grischke E, Wallwiener D, Bachmann C (2015) The prognostic role of optimal cytoreduction in advanced, bowel infiltrating ovarian cancer. J Invest Surg 28(3):160–166. https://doi.org/10.3109/08941939.2014.994794
Bartl T, Schwameis R, Stift A, Bachleitner-Hofmann T, Reinthaller A, Grimm C, Polterauer S (2018) Predictive and prognostic implication of bowel resections during primary cytoreductive surgery in advanced epithelial ovarian cancer. Int J Gynecol Cancer 28(9):1664–1671. https://doi.org/10.1097/IGC.0000000000001369
Chang SJ, Bristow RE, Chi DS, Cliby WA (2015) Role of aggressive surgical cytoreduction in advanced ovarian cancer. J Gynecol Oncol 26(4):336–342. https://doi.org/10.3802/jgo.2015.26.4.336
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383. https://doi.org/10.1016/0021-9681(87)90171-8
Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114(1):26–31. https://doi.org/10.1016/j.ygyno.2009.03.018
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250(2):187–196. https://doi.org/10.1097/SLA.0b013e3181b13ca2
Dahm-Kahler P, Palmqvist C, Staf C, Holmberg E, Johannesson L (2016) Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival—a population-based cohort study. Gynecol Oncol 142(2):211–216. https://doi.org/10.1016/j.ygyno.2016.05.025
Derlatka P, Sienko J, Grabowska-Derlatka L, Palczewski P, Danska-Bidzinska A, Bidzinski M, Czajkowski K (2016) Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer. World J Surg Oncol 14:58. https://doi.org/10.1186/s12957-016-0800-1
Dottino JA, He W, Sun CC, Zhao H, Fu S, Rauh-Hain JA, Suidan RS, Lu KH, Giordano SH, Meyer LA (2020) National trends in bowel and upper abdominal procedures in ovarian cancer surgery. Int J Gynecol Cancer 30(8):1195–1202. https://doi.org/10.1136/ijgc-2020-001243
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer-Am Cancer Soc 115(6):1234–1244. https://doi.org/10.1002/cncr.24149
Elies A, Riviere S, Pouget N, Becette V, Dubot C, Donnadieu A, Rouzier R, Bonneau C (2018) The role of neoadjuvant chemotherapy in ovarian cancer. Expert Rev Anticancer Ther 18(6):555–566. https://doi.org/10.1080/14737140.2018.1458614
Erkilinc S, Karatasli V, Demir B, Cakir I, Can B, Karadeniz T, Gokcu M, Sanci M (2018) Rectosigmoidectomy and douglas peritonectomy in the management of serosal implants in advanced-stage ovarian cancer surgery: survival and surgical outcomes. Int J Gynecol Cancer 28(9):1699–1705. https://doi.org/10.1097/IGC.0000000000001368
Feng Z, Wen H, Bi R, Yang W, Wu X (2016) Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecol Oncol 141(3):466–470. https://doi.org/10.1016/j.ygyno.2016.04.016
Gockley AA, Fiascone S, Courant KH, Pepin K, Del Carmen M, Clark RM, Goldberg J, Horowitz N, Berkowitz R, Worley M (2019) Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma. Int J Gynecol Cancer 29(3):585–592. https://doi.org/10.1136/ijgc-2018-000154
Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–374. https://doi.org/10.1007/978-1-4613-1247-5_23
Jaeger W, Ackermann S, Kessler H, Katalinic A, Lang N (2001) The effect of bowel resection on survival in advanced epithelial ovarian cancer. Gynecol Oncol 83(2):286–291. https://doi.org/10.1006/gyno.2001.6375
Kim M, Suh DH, Park JY, Paik ES, Lee S, Eoh KJ, Nam JH, Lee YY, Kim JW, Kim S (2018) Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study. J Gynecol Oncol 29(4):e60. https://doi.org/10.3802/jgo.2018.29.e60
Lee YJ, Chung YS, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT (2018) Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center. J Gynecol Oncol. https://doi.org/10.3802/jgo.2018.29.e63
Lepinay K, Szubert S, Lewandowska A, Sierant A, Wicherek L (2020) An analysis of long-term outcomes in patients treated by extensive bowel resection due to advanced ovarian cancer relative to the effectiveness of surgery. Gynecol Obstet Inves 85(2):159–166. https://doi.org/10.1159/000504538
McNamara B, Guerra R, Craig A, Chen LM, Chapman J (2021) Bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer adversely impacts survival: results from two orthogonal cohorts. Gynecol Oncol 162:S99–S100
Oseledchyk A, Hunold LE, Mallmann MR, Domrose CM, Abramian A, Debald M, Kaiser C, Kiefer N, Putensen C, Pantelis D, Fimmers R, Kuhn W, Schafer N, Keyver-Paik MD (2016) Impact of extended primary surgery on suboptimally operable patients with advanced ovarian cancer. Int J Gynecol Cancer 26(5):873–883. https://doi.org/10.1097/IGC.0000000000000707
Park SJ, Kim J, Kim SN, Lee EJ, Oh S, Seol A, Lee N, Chang SJ, Kim HS (2019) Practice patterns of surgery for advanced ovarian cancer: analysis from international surveys. Jpn J Clin Oncol 49(2):137–145. https://doi.org/10.1093/jjco/hyy175
Park SJ, Mun J, Lee EJ, Park S, Kim SY, Lim W, Song G, Kim JW, Lee S, Kim HS (2021) Clinical phenotypes of tumors invading the rectosigmoid colon affecting the extent of debulking surgery and survival in advanced ovarian cancer. Front Oncol 11:673631. https://doi.org/10.3389/fonc.2021.673631
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442
Silver DF, Zgheib NB (2009) Extended left colon resections as part of complete cytoreduction for ovarian cancer: tips and considerations. Gynecol Oncol 114(3):427–430. https://doi.org/10.1016/j.ygyno.2009.05.037
Son JH, Chang SJ (2021) Extrapelvic bowel resection and anastomosis in cytoreductive surgery for ovarian cancer. Gland Surg 10(3):1207–1211. https://doi.org/10.21037/gs-2019-ursoc-01
Tate S, Kato K, Nishikimi K, Matsuoka A, Shozu M (2017) Survival and safety associated with aggressive surgery for stage III/IV epithelial ovarian cancer: a single institution observation study. Gynecol Oncol 147(1):73–80. https://doi.org/10.1016/j.ygyno.2017.07.136
Tate S, Nishikimi K, Matsuoka A, Shozu M (2020) Aggressive surgery for advanced ovarian cancer decreases the risk of intraperitoneal recurrence. Int J Clin Oncol 25(9):1726–1735. https://doi.org/10.1007/s10147-020-01714-w
Tate S, Nishikimi K, Matsuoka A, Otsuka S, Shozu M (2022) Highly aggressive surgery benefits in patients with advanced ovarian cancer. Anticancer Res 42(7):3707–3716. https://doi.org/10.21873/anticanres.15860
Timmermans M, van der Aa MA, Lalisang RI, Witteveen PO, Van de Vijver KK, Kruitwagen RF, Sonke GS (2018) Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. Gynecol Oncol 150(3):446–450. https://doi.org/10.1016/j.ygyno.2018.07.004
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL (2018) Ovarian cancer statistics, 2018. CA Cancer J Clin 68(4):284–296. https://doi.org/10.3322/caac.21456
Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, Gynecologic Oncology G (2008) Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 26(1):83–89. https://doi.org/10.1200/JCO.2007.13.1953
Funding
The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Author information
Authors and Affiliations
Contributions
WQM: conception, data acquisition, data management, statistical analysis, critical analysis, drafting/final editing. XY, LYX, WX, GQY: critical analysis, drafting/final editing. LHH: supervision, critical analysis, drafting/final editing, guarantor.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no potential conflict of interests.
Ethical approval
This study was sanctioned by the ethical review committee of The First Affiliated Hospital of Chongqing Medical University (approval number: 2022-K114).
Consent to participate
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Wang, Qm., Xiao, Y., Liu, Yx. et al. Survival impact of bowel resection in patients with FIGO stage II–IV ovarian cancer. J Cancer Res Clin Oncol 149, 14843–14852 (2023). https://doi.org/10.1007/s00432-023-05258-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-023-05258-0